Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Tom petty free fallin

<< Previous

Bullboard Posts

Next >>

Comment by Layth1990on Jul 14, 2021 3:41pm

195 Views

Post# 33543735

RE:Tom petty free fallin

I agree, i will not buy anymore shares of this stock. I will buy only when sp hits 2.5Cad which is so possible knowing that we will have no catalysts in 6 months. Nothing matters now because the trust is broken, only starting ph3 will bump this sp.

i will be more than happy if the ceo gives his position to someone who knows what he is doing. He did tons of mistakes and dragged everyone down.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China